Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

by on November 5, 2020

Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets Proof of concept, preclinical assessment to establish activity and feasibility of the combination of Artiva’s allogeneic natural killer (NK) cells and Affimed’s innate cell engagers (ICE®) San Diego and Heidelberg, Germany, November 5, 2020…